Senior Director, Head of Immunology
Kevin has more than 20 years of industry and academia experience in immunology. After graduating magna cum laude from Washington University in St. Louis with a bachelor’s degree in Molecular Biology and Biochemistry, he moved to the Seattle for his graduate studies at the University of Washington, earning his Ph.D. in Immunology in Ed Clark’s lab studying the role of the BCR co-receptor CD22 in B cell development and activation. Kevin continued his focus on B cell biology in Klaus Rajewsky’s lab at Harvard University in Boston, where he helped establish the critical role of the BCR in mature B cell survival, proliferative responses to innate stimuli and lineage commitment.
Kevin then moved to industry in 2011, joining the Immunology Research department at Biogen where he led the pre-clinical biology efforts to discover and develop small molecule inhibitors of BTK, two of which have progressed into the clinic. Kevin also led a biologics program targeting long-lived plasma cells and was a core member of the pre-clinical team that discovered and developed a biologics candidate targeting pDC function, which is currently in Ph2 clinical trials for Lupus. In 2016, Kevin joined the Immunology Pharmacology group at AbbVie where he managed the Lupus animal model group, contributed to two bi-specific antibody programs and led the biology efforts to target a GPCR for IBD by restricting drug activity to the colon.
Kevin brings his knowledge and background in molecular and cellular immunology and experience in advancing projects from early discovery, through IND and to the clinic. He knows that the best way to make rapid progress is to build a passionate team that is focused on clear goals.